Best Writer Alternatives
Replacing Writer makes sense for teams that want to trial generative AI before buying, see published prices, or only need a simpler assistant.
Buying Writer means a sales process first. There is no trial and no public rate, so teams cannot test it on their own content before committing. Smaller groups that want a writing assistant, rather than an AI program with approvals and reporting, find it more product than they need.
Writer and its alternatives at a glance
| Tool | Best for | Starting price |
|---|---|---|
| Writer (current) | Enterprises rolling out governed generative AI company-wide | Quote-based |
| ChatGPT Enterprise | Large firms standardizing staff on OpenAI models under admin controls | $20/user/mo billed annually, or $25/user/mo billed monthly |
| Notion AI | Staff whose docs and wikis already live in Notion | Free plan |
| Infor GenAI | Infor CloudSuite customers adding AI inside existing ERP screens | Quote-based |
Companies with legal or brand review requirements for AI output get the most from Writer's approval workflows. If you only need drafting help for a few teams, per-user assistants with self-serve trials are quicker to test. Ask what your plan includes, since coverage varies by tier.
The alternatives buyers shortlist
ChatGPT Enterprise is OpenAI's company-wide ChatGPT plan, with SSO, SCIM, a Compliance API and regional data residency.
- Pricing
- Per-user pricing
- Deployment
- Cloud
- Free trial
- Not stated
Notion AI is the AI layer inside Notion's Business and Enterprise plans, with meeting notes, enterprise search and custom agents.
- Pricing
- Per-user pricing
- Deployment
- Cloud
- Free trial
- Available
Infor GenAI is the generative AI layer in Infor CloudSuite, running on Amazon Bedrock models.
- Pricing
- Custom quote
- Deployment
- Cloud
- Free trial
- Not stated
Questions buyers ask
Does Writer offer a free trial?
No. Writer's pricing is quote-based on its Standard plan, and evaluation happens through a demo with its sales team. Teams that want hands-on testing first may prefer tools with self-serve trials.